

Listing of Claims:

This listing of claims is presented for the Examiner's convenience. No amendments are made.

Listing of Claims:

1. (Previously presented) A method for treating a cancer in a human, the method comprising:
administering at least one vaccination of dendritic cells (DCs) to a human diagnosed as having a cancer; and
administering a cyclooxygenase (COX)-2 inhibitor to said human to enhance the effect of said at least one vaccination of DCs.
2. (Original) The method of claim 1, wherein each of said at least one vaccination of DC comprises from about 10^5 to about 10^7 DC.
3. (Previously presented) The method of claim 1, wherein administering said COX-2 inhibitor comprises administering said COX-2 inhibitor in a dose of from about 0.1 to about 10,000 mg per day.
4. (Previously presented) The method of claim 1, wherein administering said COX-2 inhibitor comprises administering said COX-2 inhibitor in a dose of from about 1.0 to about 1,000 mg per day.
5. (Previously presented) The method of claim 1, wherein said COX-2 inhibitor is NS-398.

6. (Previously presented) The method of claim 1, wherein the cancer is selected from the group consisting of lung cancer, bladder cancer, colorectal cancer, and brain cancer.

7. (Previously presented) The method of claim 1, wherein said cancer is selected from the group consisting of glioma, astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors.

8-11. (Canceled)

12. (Previously presented) The method of claim 1, wherein the at least one vaccination of DCs are primed.

13. (Previously presented) The method of claim 1, wherein the at least one vaccination of DCs are unprimed.

14. (Previously presented) The method of claim 1, wherein the COX-2 inhibitor is celecoxib, rofecoxib, valdecoxib, or meloxicam.

15. (Previously presented) The method of claim 1, wherein said at least one vaccination of dendritic cells (DCs) comprises mature DC.

16. (Previously presented) The method of claim 15, wherein each of said at least one vaccination of DC comprises from about 10^5 to about 10^7 mature DC.

17. (Previously presented) The method of claim 15, wherein administering said COX-2 inhibitor comprises administering said COX-2 inhibitor in a dose of from about 0.1 to about 10,000 mg per day.

18. (Previously presented) The method of claim 15, wherein administering said COX-2 inhibitor comprises administering said COX-2 inhibitor in a dose of from about 1.0 to about 1,000 mg per day.

19. (Previously presented) The method of claim 15, wherein said COX-2 inhibitor is NS 398.

20. (Previously presented) The method of claim 15, wherein the cancer is selected from the group consisting of lung cancer, bladder cancer, colorectal cancer, and brain cancer.

21. (Previously presented) The method of claim 15, wherein said cancer is selected from the group consisting of glioma, astrocytomas, ependymal tumors, glioblastoma multiforme, and primitive neuroectodermal tumors.

22. (Previously presented) The method of claim 15, wherein the at least one vaccination of DCs are primed.

23. (Previously presented) The method of claim 15, wherein the at least one vaccination of DCs are unprimed.

24. (Previously presented) The method of claim 15, wherein the COX-2 inhibitor is celecoxib, rofecoxib, valdecoxib, or meloxicam.